New approaches to combat antibiotic-resistant bacteria

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates antimicrobial resistance (AMR) by analyzing patient samples from the University Hospital of Basel. It focuses on three clinical manifestations of infectious diseases: urinary tract infections, pneumonia, and deep-seated infections caused by high-priority bacteria such as E. coli and Klebsiella species. The study employs various advanced analytical techniques, including proteomic, metabolomic, and transcriptomic analyses, to understand the physiological properties of these pathogens in infected patients. The ultimate goal is to develop new strategies and compounds to combat superbugs effectively.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with confirmed (i) urinary tract infection, (ii) pneumonia (including patients after lung transplantation, cystic fibrosis) or (iii) deep-seated infection with focus pathogen:

  * E. coli
  * Klebsiella species
  * S. aureus
  * P. aeruginosa
* Controls: no detectable bacteria in routine microbiology lab and no other infection site at inclusion of the sample and follow up for 10 days, signed general consent
* Clinical controls without obtained samples, but with confirmed (i) urinary tract infection, (ii) pneumonia (including patients after lung transplantation, cystic fibrosis) or (iii) deep-seated infection with focus pathogen:

  * E. coli
  * Klebsiella species
  * S. aureus
  * P. aeruginosa

Exclusion Criteria:

* Patients who have refused research and reuse of their data/samples (e.g. general consent) or any other decline (e.g. Patientenverfügung).
* other than one of the focus bacteria in routine microbiology lab
* Age: \<18 years
* Controls without signed general consent

Where it's running

• University Hospital Basel
  Basel, Switzerland Recruiting

Study contacts

• Principal investigator: Nina Khanna, Prof. — University Hospital Basel, Division of Infectiology
• Study coordinator: Nina Khanna, Prof.
• Email: nina.khanna@usb.ch
• Phone: +41 61 328 73 25

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sepsis Chart Implementation and 7-Day Mortality in Indonesian Hospitals

  This study tests whether using a paper-based sepsis chart helps doctors treat sepsis faster and see if it lowers 7-day deaths for adults in two Jakarta hospitals.

  Recruiting Dr Cipto Mangunkusumo General Hospital · Jakarta Pusat, DKI Jakarta and 1 other locations · NCT07843277

• Molecular tests to speed up sepsis microbe ID at Indonesia’s national referral hospital

  This study tests whether Hybrispot DNA Flow and metagenomic sequencing can identify sepsis-causing microbes faster than standard blood culture in adult patients at a major Indonesian hospital.

  Recruiting Dr Cipto Mangunkusumo General Hospital · Jakarta, DKI Jakarta · NCT07841535

• Evaluating the effectiveness of CAZ/AVI and FOS for treating CRE infections

  This study is testing whether a combination of two antibiotics, ceftazidime/avibactam and fosfomycin, can help adults with tough infections caused by drug-resistant bacteria feel better.

  Recruiting at 2 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna and 1 other locations · NCT06717594

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.